PRF Technologies (PRFX) vs XORTX Therapeutics (XRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
XORTX Therapeutics is the larger company by market cap ($3.4 million vs $3.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRFX | XRTX |
|---|---|---|
| Share price | $0.8587 | $1.85 |
| Market cap | $3.00M | $3.36M |
| 1-day change | -2.16% | +6.02% |
| Forward P/E | — | 2.31 |
| EPS (TTM) | $-4.09 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.95 | $7.05 |
| 52-week low | $0.851 | $1.59 |
| Distance from 52-week high | -89.20% | -73.76% |
| Average volume | 294.15K | 376.30K |
| Shares outstanding | 3.50M | 1.82M |
| Employees | 6 | — |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About PRF Technologies
PRFX stock →PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
Healthcare · Drug Manufacturers - Specialty & Generic · 6 employees
About XORTX Therapeutics
XRTX stock →XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Healthcare · Biotechnology
PRFX vs XRTX FAQ
Which is bigger, PRF Technologies or XORTX Therapeutics?
XORTX Therapeutics (XRTX) is larger, with a market capitalization of $3.36M compared with $3.00M for PRF Technologies (PRFX).
Are PRF Technologies and XORTX Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for PRF Technologies and Biotechnology for XORTX Therapeutics.